Ramipril vs Amlodipine
Clinical Comparison
Clinical Context
NICE hypertension guidelines (NG136) recommend ACE inhibitors as step 1 for patients under 55 and non-Black patients, while calcium channel blockers are step 1 for patients aged 55+ or of Black African/Caribbean descent. Many patients end up on both as combination therapy at step 2.
Drug Profiles
Ramipril
ACE inhibitor
Mechanism
Inhibits angiotensin-converting enzyme, reducing angiotensin II production and aldosterone secretion; also reduces bradykinin breakdown
Indications
- Hypertension
- Heart failure (post-MI and chronic)
- Diabetic nephropathy
- Cardiovascular risk reduction (HOPE trial)
Common Doses
1.25 mg OD initially, titrated to 10 mg OD
Route
Oral
Onset & Duration
Onset 1-2 hours; peak 3-6 hours; duration 24 hours
Amlodipine
Calcium channel blocker (dihydropyridine)
Mechanism
Blocks L-type voltage-gated calcium channels in vascular smooth muscle, causing arterial vasodilation and reducing peripheral resistance
Indications
- Hypertension
- Stable angina pectoris
- Vasospastic (Prinzmetal) angina
Common Doses
5 mg OD, increased to 10 mg OD if needed
Route
Oral
Onset & Duration
Onset 6-12 hours; peak 6-12 hours; half-life 35-50 hours
Key Differences
| Category | Ramipril | Amlodipine |
|---|---|---|
| First-line population (NICE) | Age <55, non-Black (also if diabetes or HF) | Age >=55, or Black African/Caribbean ethnicity |
| Renoprotection | Proven renoprotective in diabetic nephropathy | No renoprotective effect |
| Heart failure | First-line in HFrEF — reduces mortality | No mortality benefit in HF; may worsen decompensation |
| Common side effect | Dry cough (10-15%) | Ankle oedema (5-10%) |
| Potassium effect | Raises potassium — risk of hyperkalaemia | No significant effect on potassium |
| Pregnancy | Contraindicated in all trimesters | Avoid — limited safety data, but less teratogenic than ACEi |
First-line population (NICE)
Age <55, non-Black (also if diabetes or HF)
Age >=55, or Black African/Caribbean ethnicity
Renoprotection
Proven renoprotective in diabetic nephropathy
No renoprotective effect
Heart failure
First-line in HFrEF — reduces mortality
No mortality benefit in HF; may worsen decompensation
Common side effect
Dry cough (10-15%)
Ankle oedema (5-10%)
Potassium effect
Raises potassium — risk of hyperkalaemia
No significant effect on potassium
Pregnancy
Contraindicated in all trimesters
Avoid — limited safety data, but less teratogenic than ACEi
Key Advantages
Ramipril
- Renoprotective in diabetic nephropathy
- Reduces cardiovascular mortality post-MI
- First-line in heart failure with reduced EF
- Well-established evidence for CV risk reduction
Amlodipine
- No cough side effect
- Effective across all ethnic groups (particularly Afro-Caribbean patients)
- Long half-life allows once-daily dosing with stable BP control
- Safe to combine with ACE inhibitors or ARBs
Key Cautions
Ramipril
- Dry cough (10-15% of patients — switch to ARB)
- Hyperkalaemia risk — monitor potassium
- Angioedema (rare but serious)
- Contraindicated in pregnancy
- Avoid with potassium-sparing diuretics without monitoring
Amlodipine
- Peripheral oedema (dose-dependent, common at 10 mg)
- Headache and flushing
- Avoid in severe aortic stenosis
- Not cardioprotective in heart failure (unlike ACEi)
Clinical Verdict
Choose ramipril if the patient has diabetes, CKD, heart failure, or post-MI. Choose amlodipine if the patient is aged 55+, Black African/Caribbean, or intolerant of ACE inhibitors. Both are commonly combined at NICE step 2.
Medical Disclaimer: This comparison is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making prescribing decisions. Verify all drug information with current clinical guidelines (BNF, NICE, SmPCs).
Full monographs for Ramipril & Amlodipine in the MedNext app
Complete dosing, interactions, contraindications, side effects, and more — covering 2,866 drugs with AI-powered search.
Download MedNext Formulary